Big Phar­ma back­ers jump on board 'Treg' car­tog­ra­pher's lead round with up to six can­di­dates in the pipe

Among the wealth of emerg­ing tar­gets in on­col­o­gy, im­mune sys­tem sup­press­ing reg­u­la­to­ry T cells — bet­ter known as “Tregs” — have earned some big-name in­ter­est in re­cent years. Now, a West Coast start­up map­ping Tregs in hu­man tis­sue has scored a slate of Big Phar­ma back­ers to dri­ve its grow­ing pipeline in­to the clin­ic.

South San Fran­cis­co-based TRexBio emerged from stealth Tues­day with a $59 mil­lion Se­ries A and the back­ing of in­vest­ment funds from Big Phar­ma gi­ants Eli Lil­ly, J&J and Pfiz­er, the biotech said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER